S. 1041 · 119th Congress · Commerce
Affordable Prescriptions for Patients Act
Limits patents a biologic drug manufacturer can assert against biosimilar competitors in certain lawsuits. AI-read
- IntroducedMar 13, 2025 Done
- CommitteeReported Apr 10, 2025 Done
- Senate floorPassed by unanimous consent · Jul 21, 2026 Done
- House floorAwaiting vote Current stage
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.)
The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug.
The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 13, 2025
Who lobbies on it
18 organizations, more than 98% of Senate bills · 146 filings · Q1 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
7 of 7 quarters
“Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
America's Health Insurance Plans Inc (ahip)
7 of 7 quarters
“…S. 1041 - Affordable Prescriptions for Patients Act - Sen. Cornyn, John - Patent issues S. 1095 - Stop STALLING Act - Sen. Klobuchar, Amy - Drug patent reform S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy - Drug patent reform S. 1414 - Expedited Access to Biosimilars Act…”
$11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Pfizer, Inc.
7 of 7 quarters
“Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.”
$9.9M lobbying spend in 2026 to date, all issuesQ3 2026 filing
15 more organizations, every filingPROUpgrade
Organizations that named S. 1041 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
10 actions · newest first- Jul 21, 2026Held at the desk.
- Jul 21, 2026Received in the House.
- Jul 21, 2026Message on Senate action sent to the House.
- Jul 21, 2026Passed Senate with amendments by Unanimous Consent. (consideration: CR S4198-4199; text: CR S4199)
Show all 10 actionsShow fewer
- Jul 21, 2026Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.
- Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.
- Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
- Apr 3, 2025Committee on the Judiciary. Ordered to be reported with amendments favorably.
- Mar 13, 2025Read twice and referred to the Committee on the Judiciary.
- Mar 13, 2025Introduced in Senate
What members said about it
-
Senate Judiciary Committee Advances Six Bipartisan Bills To Lower Prescription Drug Prices
This morning, the U.S. Senate Judiciary Committee advanced six bipartisan bills to help lower the price of prescription drugs.
“Families are struggling to afford their medications. Congress must take an all-options approach to lowering prescription drug prices, and the bills we advanced today embody that spirit. The legislative package will improve coordination between agencies, bring generic drugs to market more quickly, and foster competition…”